Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Anesthesiol Clin ; 41(3): 531-548, 2023 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-37516493

RESUMEN

With a rapidly aging population and increasing global surgical volumes, managing the elevated risk of perioperative pulmonary complications has become an expanding focus for quality improvement in health care. In this narrative review, we will analyze the evidence-based literature to provide high-quality and actionable management strategies to better detect, stratify risk, optimize, and manage perioperative pulmonary complications in geriatric populations.


Asunto(s)
Envejecimiento , Complicaciones Posoperatorias , Humanos , Anciano , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/terapia , Atención Perioperativa
2.
A A Pract ; 17(1): e01657, 2023 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-36706162

RESUMEN

Systemic anticoagulation is a relative contraindication for performing nasal intubation due to the risk of hazardous bleeding. However, nasal intubation may sometimes be the only way to facilitate surgical exposure. There are currently no recommendations in the literature to safely perform nasal intubation in anticoagulated patients. This case series describes 4 patients, all receiving systemic anticoagulation for carotid endarterectomy, who received nasal intubation using a telescoping approach. None of them had any epistaxis. Telescoping the endotracheal tube using a red rubber catheter may be an effective and safe method for nasal intubation when there is a high risk of epistaxis.


Asunto(s)
Endarterectomía Carotidea , Epistaxis , Humanos , Epistaxis/etiología , Intubación Intratraqueal/métodos , Anticoagulantes
3.
J Surg Res ; 279: 148-163, 2022 11.
Artículo en Inglés | MEDLINE | ID: mdl-35777347

RESUMEN

INTRODUCTION: Many deaths after surgery can be attributed to "failure to rescue," which may be a better surgical quality indicator than the occurrence of a postoperative complication. Acute kidney injury (AKI) is one such postoperative complication associated with high mortality. The purpose of this study is to identify perioperative risk factors associated with failure to rescue among patients who develop postoperative AKI. METHODS: We identified adult patients who underwent non-cardiac surgery between 2012 and 2018 and experienced postoperative severe AKI (an increase in blood creatinine concentration of >2 mg/dL above baseline or requiring hemodialysis) from the American College of Surgeons National Surgical Quality Improvement Program database. Multivariable logistic regression was used to identify risk factors for failure to rescue among patients who developed severe AKI. RESULTS: Among 5,765,904 patients who met inclusion criteria, 26,705 (0.46%) patients developed postoperative severe AKI, of which 6834 (25.6%) experienced failure to rescue. Risk factors with the strongest association (adjusted odds ratio >1.5) with failure to rescue in patients with AKI included advanced age, higher American Society of Anesthesiologists class, presence of preoperative ascites, disseminated cancer, septic shock, and blood transfusion within 72 h of surgery start time. CONCLUSIONS: About one-fourth of patients who develop severe AKI after non-cardiac surgery die within 30 d of surgery. Both patient- and surgery-related risk factors are associated with this failure to rescue. Further studies are needed to identify early and effective interventions in high-risk patients who develop postoperative severe AKI to prevent the antecedent mortality.


Asunto(s)
Lesión Renal Aguda , Lesión Renal Aguda/epidemiología , Lesión Renal Aguda/etiología , Lesión Renal Aguda/terapia , Adulto , Creatinina , Humanos , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/terapia , Periodo Posoperatorio , Estudios Retrospectivos , Factores de Riesgo
4.
Can J Anaesth ; 68(1): 81-91, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-33029686

RESUMEN

PURPOSE: Perioperative complications of patients with idiopathic pulmonary fibrosis (IPF) are not well described. The aim of this study was to identify risk factors associated with adverse postoperative outcomes in IPF patients. METHODS: We performed a single-centre historical cohort study of adult patients with IPF who underwent surgery between 2008 and 2018. We analyzed the prognostic utility of select perioperative factors for postoperative acute exacerbation of IPF (AE-IPF), acute respiratory worsening (ARW), pneumonia, and 30-day and one-year mortality using univariable and multivariable regression analyses. To adjust for multiple interactions, the false discovery rate (Q value) was utilized to appropriately adjust P values and a Q value < 0.05 was considered to be significant. RESULTS: Two hundred and eighty-two patients were identified. After excluding emergency cases and bronchoscopies performed for active pneumonia, 14.2% of the cohort developed ARW that persisted > 24 hr after surgery, 5.0% had AE-IPF, and 9.2% were diagnosed with postoperative pneumonia within 30 days of surgery. The 30-day mortality was 6.0% and the one-year mortality was 14.9%. Preoperative home oxygen use (relative risk [RR], 2.70; 95% confidence interval [CI], 1.50 to 4.86; P < 0.001) and increasing surgical time (per 60 min) (RR, 1.03; 95% CI, 1.02 to 1.05; P < 0.001) were identified as independent risk factors for postoperative ARW. CONCLUSIONS: In IPF patients, preoperative home oxygen requirement and increasing surgical time showed a strong relationship with postoperative ARW and may be useful markers for perioperative risk stratification. Facteurs de risque périopératoires des patients atteints de fibrose pulmonaire idiopathique : une étude de cohorte historique.


RéSUMé: OBJECTIF: Les complications périopératoires chez les patients atteints de fibrose pulmonaire idiopathique (FPI) ne sont pas bien décrites. L'objectif de cette étude était d'identifier les facteurs de risque associés aux devenirs postopératoires défavorables chez les patients atteints de FPI. MéTHODE: Nous avons réalisé une étude de cohorte historique monocentrique portant sur des patients adultes atteints de FPI et ayant subi une chirurgie entre 2008 et 2018. Nous avons analysé l'utilité pronostique de facteurs périopératoires choisis pour l'exacerbation postopératoire aiguë de la FPI, la détérioration respiratoire aiguë, la pneumonie, et la mortalité à 30 jours et à un an à l'aide d'analyses de régression univariées et multivariées. Afin de tenir compte d'interactions multiples, le taux de fausses découvertes (valeur Q) a été utilisé pour ajuster adéquatement les valeurs P, et une valeur Q < 0,05 a été considérée significative. RéSULTATS: Deux cent quatre-vingt-deux patients ont été identifiés. Après avoir exclu les cas en urgence et les bronchoscopies réalisées lors de pneumonie active, 14,2 % des patients de la cohorte ont souffert d'une détérioration respiratoire aiguë qui a persisté > 24 h après la chirurgie, 5,0 % ont subi une exacerbation aiguë de la FPI, et 9,2 % ont reçu un diagnostic de pneumonie postopératoire dans les 30 jours suivant leur chirurgie. La mortalité à 30 jours était de 6,0 %, et la mortalité à un an de 14,9 %. L'utilisation préopératoire d'oxygène à domicile (risque relatif [RR], 2,70; intervalle de confiance [IC] 95 %, 1,50 à 4,86; P < 0,001) et l'augmentation du temps chirurgical (par tranche de 60 min) (RR, 1,03; IC 95 %, 1,02 à 1,05; P < 0,001) ont été identifiées comme des facteurs de risque indépendants de détérioration respiratoire aiguë en période postopératoire. CONCLUSION: Chez les patients atteints de FPI, une forte association a été observée entre les besoins préopératoires en oxygène au domicile ainsi que l'augmentation du temps chirurgical et la détérioration respiratoire aiguë en période postopératoire; ces deux facteurs pourraient constituer des marqueurs utiles pour stratifier le risque en période périopératoire.


Asunto(s)
Fibrosis Pulmonar Idiopática , Adulto , Estudios de Cohortes , Progresión de la Enfermedad , Humanos , Pronóstico , Estudios Retrospectivos , Factores de Riesgo
5.
Curr Anesthesiol Rep ; 10(4): 512-521, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32904358

RESUMEN

PURPOSE OF REVIEW: Systemic sclerosis or scleroderma (SSc) is a systemic, immune-mediated disease characterized by abnormal cutaneous and organ-based fibrosis that results in progressive end-organ dysfunction and decreased survival. SSc results in significant challenges for the practicing anesthesiologist due to its rarity, multi-system involvement, and limited evidence-based guidance for optimal perioperative care. In this update, we briefly discuss the recent evidence on the pathophysiology and current management of SSc, review the anesthesia-related literature, and extrapolate these observations into an optimal perioperative strategy for the care of SSc patients. RECENT FINDINGS: Evidence shows that patients with SSc demonstrate an increased risk for perioperative myocardial infarction, high rates of interstitial lung disease, pulmonary arterial hypertension, neurological disease, gastric dysmotility disorders, and challenging airway management, all findings that may result in suboptimal perioperative outcomes. SUMMARY: Advances in SSc medical management have resulted in improved survival, likely increasing the number of patients who will be exposed to perioperative care. Optimal perioperative management and risk stratification should expand beyond the well-described airway challenges and consider numerous systemic manifestations of systemic sclerosis such as pulmonary arterial hypertension, interstitial lung disease, and cardiac sequelae.

6.
Clin Ther ; 33(11): 1844-50, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22018680

RESUMEN

BACKGROUND: The Intermountain Cystic Fibrosis Pediatric Center utilizes ticarcillin-clavulanate 400 mg/kg/d divided every 6 hours, (maximum 24 g/d). This dosing strategy is higher than the Food and Drug Administration (FDA)-approved package labeling. We evaluated the microbiologic efficacy of this dosing regimen. OBJECTIVES: The primary study objective was to predict the pharmacokinetic (PK) and pharmacodynamic (PD) MIC breakpoints (the highest MIC with a probability of target attainment [PTA] of at least 90%) for the bacteriostatic and bactericidal targets of ticarcillin activity against Pseudomonas aeruginosa using the study dosing regimen. A secondary objective was to evaluate the tolerability profile of the higher ticarcillin-clavulanate dosing regimen in children with cystic fibrosis (CF). METHODS: This was a population-based PK-PD modeling study of pediatric CF patients admitted from January 1, 2005 to December 31, 2009 who received the dosing regimen for at least 7 days. Population PK and PD models were used to estimate PK and PD parameters for 127 clinically evaluable patients. A 10,000-patient Monte Carlo simulation was performed to estimate the target time in which free drug concentrations exceeded the MIC of the infecting organism. The 2 PK-PD targets of microbiologic efficacy included ≥30% for bacteriostasis and ≥50% for bactericidal effects of ticarcillin-clavulanate at higher than FDA-approved doses. RESULTS: A total of 127 patients (age, 0-19 years) met inclusion criteria. Serum concentration levels were modeled in this patient population using published PK parameters with intermittent ticarcillin peak concentrations reaching 288 (93.4) mg/L. The model predicted the PTA of the MICs for P. aeruginosa with a near-maximal bactericidal PK-PD MIC breakpoint of 16 µg/mL and a bacteriostasis PK-PD MIC breakpoint of 32 µg/mL. CONCLUSIONS: The results of our simulation suggest that in this select pediatric population, higher than FDA-approved doses of ticarcillin-clavulanate were effective in achieving bactericidal effects among pseudomonal isolates with MICs <16 µg/mL. Bacteriostatic and bactericidal effects were not frequently achieved among P. aeruginosa isolates with MICs >32 µg/mL. Additional studies are warranted to determine the clinical effectiveness of this dosing regimen.


Asunto(s)
Antibacterianos/administración & dosificación , Fibrosis Quística/tratamiento farmacológico , Adolescente , Antibacterianos/farmacocinética , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Área Bajo la Curva , Niño , Preescolar , Ácidos Clavulánicos/administración & dosificación , Ácidos Clavulánicos/farmacocinética , Ácidos Clavulánicos/farmacología , Ácidos Clavulánicos/uso terapéutico , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Humanos , Lactante , Recién Nacido , Pruebas de Sensibilidad Microbiana , Ticarcilina/administración & dosificación , Ticarcilina/farmacocinética , Ticarcilina/farmacología , Ticarcilina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA